The Bespoke Gene Therapy Consortium, managed by the Foundation for the National Institutes of Health, aims to accelerate the development process for gene therapies targeting rare diseases—conditions for which there are currently few therapeutic options. The public-private partnership selected the first eight rare diseases in May for its clinical trials program.

As with the Massachusetts layoffs announced two weeks ago, a Takeda spokesperson stated that the cuts in California are directly related to the company’s decision to discontinue discovery and pre-clinical efforts in AAV gene therapy as well as research and pre-clinical efforts in rare hematology.